/

ADAG

Adagene Inc.After hours

2.29−0.17 −6.91%USD

NasdaqGM · as of Oct 14, 16:00 ET · 15m delay

Open

2.35

Prev close

2.46

Day range

2.252.50

52-week range

1.304.85

Volume

898.86K3.41×

Mkt cap

153.76M

P/E ttm

—

Fwd P/E

-4.09

EPS ttm

-0.3700

Div yield

0.00%

Earnings

—

From 52w high

−52.78%

Price Chart

Yahoo Finance · delayed

ADAGOct 14, 2026O 2.35H 2.50L 2.25C 2.29−0.17 (−6.91%)Vol 898.86K

SMA 503.42
SMA 2003.38

1Y change +19.90% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ADAG Adagene Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −18.51%
1 month: −29.97%
3 months: −37.60%
6 months: −40.05%
Year to date: +21.16%
1 year: +24.46%

Valuation & ownership

Market cap: 153.76M
Enterprise value: 59.90M
P/E (ttm): —
Forward P/E: -4.09
PEG ratio: —
Price / book: 1.72
Price / sales (ttm): 16.55
EV / EBITDA: -2.73
EPS (ttm): -0.3700
EPS (forward): -0.5600
Beta (5y monthly): 0.54
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 67.14M
Float: 42.09M
Short % of float: 3.70%
Short ratio (days): 8.51
Held by insiders: 11.40%
Held by institutions: 36.04%
Avg volume (3m): 263.94K
50-day average: 3.44
200-day average: 3.38
52-week change: +24.46%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 25.7
vs 50-day SMA: −32.97%
vs 200-day SMA: −32.28%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 12.12%
Realised vol (20d, ann.): 76.8%
From 52-week high: −52.78%
From 52-week low: +76.15%

ANR

Analyst Consensus

6 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

9.91

+332.68% implied

Low 7.00Median 8.50High 17.45

Recommendation trend

Now6 / 0 / 0
1m ago5 / 1 / 0

DES

About Adagene Inc.

Yahoo Finance profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Sector: Healthcare
Industry: Biotechnology
Employees: 128
Headquarters: Suzhou, China
Website: adagene.com
Officers: Dr. Peter P. Luo Ph.D. Co- Founder, Chairman, CEO and President of R&D
Mr. Man Kin Tam M.B.A.

SEAS

Seasonality · ADAG

2021–2026 · monthly returns

Strongest month Jan +29.91%Weakest month Mar −22.43%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	45.5	7.6	32.4	-6.1	7.9	5.8	-10.7	-6.4	-8.8	-28.4			+21.2%
2025	-4.5	5.8	-24.4	0.0	27.6	0.5	2.1	7.0	-6.6	-10.6	12.9	-6.0	−5.0%
2024	89.5	-12.6	-12.5	-19.3	23.9	9.3	-16.4	9.4	-20.7	28.4	-18.1	-14.8	+3.1%
2023	44.9	-13.3	-12.9	-9.7	0.8	12.1	-8.1	0.0	12.5	-11.4	29.2	10.3	+45.7%
2022	-10.3	-24.9	-35.7	4.3	-23.3	-26.2	-18.2	-13.6	-12.3	-29.7	20.0	22.7	−83.6%
2021			-26.7	-18.7	-2.9	-4.4	14.1	4.5	-11.1	-21.8	-26.9	-1.8	−67.1%

INSD

Insider Activity · ADAG

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 13, 2026	Do Cuong VietDirector	Purchase at price 3.75 per share.	2K	$7.50K

13F

Investors Holding ADAG

latest 13F filings of 29 followed managers

Investors holding ADAG
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$615.3K	0.00%	146.50K	+324%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ADAG

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ADAG

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Adagene Inc.

Seasonality · ADAG

Insider Activity · ADAG

Congress Trades · ADAG

Investors Holding ADAG

Investors Holding ADAG

Congress Trades · ADAG

Seasonality · ADAG

Insider Activity · ADAG

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Adagene Inc.

Financial Snapshot

Earnings & Dividends

News